Soligenix Inc. SNGX Archives

TuesdaySep 09, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation

At its core, Soligenix is a late-stage biopharmaceutical company that thrives at the intersection of urgent medical need and scientific innovation. SNGX’s Specialized BioTherapeutics division is anchored by its proprietary HyBryte(TM) (“SGX301”), a novel photodynamic therapy for CTCL. Soligenix’s Public Health Solutions division positions the company as an important contributor to biodefense and emerging infectious disease. Soligenix (NASDAQ: SNGX) has taken a bold step forward with its latest corporate presentation, offering investors and the broader biotech community a deeper look into the company’s evolving strategy and pipeline (https://ibn.fm/YGu4N). The presentation underscores Soligenix’s dual focus: pioneering therapies for rare diseases that…

ThursdaySep 04, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation

The FDA’s orphan drug designation for dusquetide follows encouraging phase 2a clinical trial results demonstrating both biological efficacy and a favorable safety profile. CEO notes that “the FDA's decision to grant orphan drug designation to the SGX945 program signifies an important step for Soligenix.” Phase 2a pilot data demonstrated clinically meaningful improvements in oral aphthous ulcer healing. Soligenix (NASDAQ: SNGX) has taken a decisive step forward in the fight against rare diseases, announcing that the FDA has granted orphan drug designation to its investigational therapy dusquetide for the treatment of Behçet’s disease (https://ibn.fm/0t1aK). This key FDA designation underscores not only…

TuesdaySep 02, 2025 11:00 am

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at H.C. Wainwright Global Investment Conference

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place Sept. 8–10, 2025. The on-demand presentation will be available beginning Sept. 5 at 7 a.m. ET through the conference platform, with Soligenix management also participating in one-on-one meetings during the event. To view the full press release, visit https://ibn.fm/WGwBN About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where…

TuesdayAug 26, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline

CEO reports confidence about late-stage rare disease pipeline and upcoming key development milestones. Soligenix’s recent accomplishments reflect substantial momentum across its specialized biotherapeutics and public health solutions business segments. The company's pipeline diversification strategy extends beyond CTCL treatment to encompass multiple therapeutic areas. With pivotal phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies advancing through late-stage development, Soligenix (NASDAQ: SNGX) stands at the threshold of potentially transforming treatment paradigms for rare diseases affecting millions of underserved patients worldwide. The Soligenix pipeline includes a novel photodynamic drug therapy, along with other innovative drug and vaccine technology, to…

FridayAug 15, 2025 12:45 pm

Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy

Ricin toxin is a potent biothreat, so lethal that even a dose the size of a grain of salt can be fatal within 48 to 72 hours. RiVax(R) is a subunit protein vaccine that incorporates Soligenix’s ThermoVax(R) technology, which eliminates the need for cold-chain storage. Soligenix reports that the RiVax antigen has been shown to be safe in phase 1 studies in humans, with future steps including pivotal animal efficacy studies. With global security threats driving demand for advanced biodefense solutions, Soligenix (NASDAQ: SNGX) is advancing RiVax(R), a heat-stable recombinant vaccine candidate aimed at protecting against deadly ricin toxin exposure.…

ThursdayAug 14, 2025 9:25 am

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Q2 2025 Results Highlight Progress in Late-Stage Rare Disease Pipeline

Soligenix (NASDAQ: SNGX), a late-stage biopharma company developing treatments for rare diseases, reported Q2 2025 results and recent milestones. The company expects top-line Phase 2a results for SGX302 in mild-to-moderate psoriasis before year-end, along with continued updates from its investigator-initiated study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL). A confirmatory Phase 3 trial of HyBryte(TM) in early-stage CTCL is actively enrolling, with results anticipated in 2026. Soligenix also completed a Phase 2a proof-of-concept study of SGX945 for Behçet’s Disease, achieving its primary objective of demonstrating biological efficacy, and transferred manufacturing of synthetic hypericin to the U.S. under its Sterling…

MondayAug 11, 2025 9:50 am

QualityStocksNewsBreaks – Alliance Global Partners Maintains Buy Rating, Increases Price Target as Soligenix Inc. (NASDAQ: SNGX) Advances Proprietary Clinical Programs

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted last week in a report from Alliance Global Partners (“AGP”), which maintained its Buy rating for Soligenix and raised SNGX’s price target to $10 per share. According to the report, the increase was based on the increasing valuation of HyBryte(TM) for the treatment of early-stage cutaneous T cell lymphoma (“CTCL”) and new estimated valuation for Soligenix’s SGX945, a treatment for Behçet's disease. According to the report, SNGX’s phase 3 FLASH2 trial is on track to have topline results announced next year. AGP noted that in December 2024, Soligenix…

ThursdayJul 31, 2025 9:10 am

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Achieves Biological Efficacy in Phase 2a SGX945 Study for Behçet’s Disease

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing products for rare diseases, has completed its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in Behçet's Disease, meeting the objective of demonstrating biological efficacy. In the open-label trial, SGX945 achieved a 40% improvement in the primary ulcer endpoint versus a historical placebo group from the apremilast (Otezla(R)) Phase 3 study, matching or exceeding apremilast outcomes despite treatment stopping at four weeks. Seven of eight patients reported reduced ulcer duration, number and pain, with benefits persisting through the follow-up period and no treatment-related adverse events reported. CEO Christopher J. Schaber said…

ThursdayJul 24, 2025 12:00 pm

Soligenix Inc. (NASDAQ: SNGX) Pioneering Oral Mucositis Treatment with Novel Therapeutic, Promising Study Results

Severe oral mucositis (“SOM”) often necessitates hospitalization, opioid pain management and feeding tube placement, substantially lowering quality of life. Soligenix has taken on this challenge with SGX942, a treatment aimed at reducing tissue inflammation, promoting healing and supporting immune response. The company is in the process of analyzing combined phase 2 and 3 datasets to design a second phase 3 study. Oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment, continues to wreak havoc on patients undergoing cancer care, prompting an urgent need for effective interventions. Soligenix (NASDAQ: SNGX) is stepping forward with SGX942, a novel…

FridayJul 18, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial

Recent data indicates Soligenix’s HyBryte(TM) is showing promising treatment success in early-stage cutaneous T-cell lymphoma. “With limited treatment options, especially in the early stages of their disease, CTCL patients are often searching for alternative treatments,” leading investigator states. No new FDA-approved, skin-directed therapies have been introduced in more than a decade, and conventional options carry risks. Soligenix (NASDAQ: SNGX) is reporting encouraging interim outcomes from the ongoing investigator-initiated study (“IIS”) of its HyBryte(TM) (synthetic hypericin) program, under the direction of Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program. Kim is a leading enroller in Soligenix’s phase 3 FLASH study…

Site Search

Company Search

Tag: Soligenix Inc. SNGX